One of the presenters yesterday at the JPMorgan health care conference was pharmaceuticals company Dendreon (OTC:DNDNQ), which is a stock that gets a lot of interest on Fool.com. Having already presented the bull side of the stock in a previous video, Motley Fool health care bureau chief Brenton Flynn now turns his attention to what Dendreon bears are honing in from the conference. He discusses the terse guidance coming from the company, how Dendreon's new approach to promoting Provenge could be wasteful, and advancing competition.